Papaverine - instructions for use, dose, side effects, contraindications

Papaverine hydrochloride lowers the tone of smooth muscles and therefore has a vasodilating and spasmolytic effect. It is an inhibitor of the enzyme phosphodiesterase and causes intracellular accumulation of cyclic 3,5-adenosine monophosphate and a decrease in the calcium content, which leads to a violation of contractility of smooth muscles and their relaxation in spastic states. The effect of papaverine hydrochloride on the central nervous system is poorly expressed, but only in large doses it has some sedative effect.In large doses reduces the excitability of the heart muscle and slows intracardiac conduction.

Pharmacokinetics:

Adsorption is high. It penetrates through the histohematological barriers.

Metabolised in the liver. Half-life is 0.5 - 2 hours.

It is excreted by the kidneys (in the form of metabolites).

Indications:

Papaverine hydrochloride is used to prevent and treat functional disorders and pain, associated with spasms smooth musculature of vessels, organs of the abdominal cavity and bronchi.

Assign with spasms of peripheral vessels (endarteritis, etc.), vessels of the head brain, angina (in composition of integrated therapy), bronchospasm, spasms smooth musculature bodies abdominal cavities (pilorospasm, spastic colitis, cholecystitis, attacks of cholelithiasis), with spasms of the urinary tract, renal colic.

Contraindications:

Increased susceptibility to the drug, AV blockade, glaucoma, severe hepatic failure, old age (risk of hyperthermia), children under 1 year.

Carefully:With caution (in small doses) - a condition after a craniocerebral injury, chronic renal insufficiency adrenal glands, hypothyroidism, hyperplasia of the prostate, supraventricular tachycardia, shock states.

Pregnancy and lactation:In pregnancy and lactation, the safety of the drug is not established.

Dosing and Administration:

Inside adults take 40-80 mg 3-4 times a day; children 2-4 times a day: at the age of 1 to 2 years - 5 mg per reception, 3-4 years - 5-10 mg; 5-6 years - 10 mg each; 7-9 years - 10-15 mg each; 10-14 years - for 15-20 mg.

Higher doses for adults inside: single dose of 200 mg, daily 600 mg.

Higher doses for children inside at the age of 1 year: single 5 mg, daily 10 mg, at the age of 2 years - single 10 mg, daily 20 mg; 3-4 years - single 15 mg, daily - 30 mg; 5-6 years, single 20 mg, daily - 40 mg; 7-9 years of age 30 mg, daily - 60 mg; 10-14 years, single 50-60 mg, daily 100-200 mg.

Dosage of less than 10 mg is prepared in the production department of the pharmacy.

Side effects:

Allergic reactions are possible, partial or complete atrioventricular blockade, ventricular extrasystole, decreased blood pressure, constipation, drowsiness, increased activity of "hepatic" transaminases, eosinophilia.

Overdose:

Symptoms: diplopia, weakness, decreased blood pressure, drowsiness.

Treatment: symptomatic (maintenance of blood pressure).

Interaction:

Reduces the antiparkinsonian effect of levodopa and hypotensive effect of methyldopa.In combination with barbiturates, the spasmolytic effect of papaverine hydrochloride is enhanced. When combined with tricyclic antidepressants, procainamide, reserpine, quinidine sulfate, hypotensive effect may increase.

Special instructions:

During the treatment period, alcohol intake should be excluded.

In pregnancy and lactation, the safety of the drug is not established.

The vasodilating effect is reduced by smoking.

Form release / dosage:

Tablets of 40 mg.

Packaging:

For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

2 contour packs with instructions for use are placed in a pack of cardboard.

For 10 tablets in a contour non-cellular package of paper with a polymer coating.

800 contour mesh or 700 contour non-jawed packages with an equal number of instructions for use are placed in a group package.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

5 years. After expiration date the drug should not be used.

Terms of leave from pharmacies:Without recipe

Registration number:LSR-007267/08

Date of registration:10.09.2008

The owner of the registration certificate:AVEKSIMA, JSC AVEKSIMA, JSC Russia

Manufacturer: & nbsp

IRBITSK HFZ, OJSC Russia

Information update date: & nbsp22.08.2015

Illustrated instructions

Instructions

Papaverine (Papaverine)